Bio-Techne announced the publication of a recent validation study demonstrating that the proprietary exosome-based liquid biopsy tests from Bio-Techne’s Exosome Diagnostics brand may be used to assess the mutational status of the Epidermal Growth Factor Receptor – or EGFR – gene in patients with non-small cell lung cancer. The data from this study will be available to discuss at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago. The study published in Oncotarget describes Bio-Techne’s proprietary technique to co-isolate exosomal RNA/DNA and cell-free tumor DNA in a single step, followed by a qPCR-based assay to detect 29 different types of mutations in EGFR. Highlights of the data include: the extended EGFR panel achieved a sensitivity of 92% and 95% both at 100% specificity, and 86% sensitivity for exon 19 indels at 94% specificity in patients with M1b extra-thoracic disease. Including the challenging patients with intrathoracic disease resulted in a sensitivity of 90%, 83% and 73% for exon 19 indels.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.